Table 4.

Clinical characteristics, follow-up, and outcomes of EXT1/EXT2-positive and EXT1/EXT2-negative LMN, with and without LN (combined class 5 LMN with or without class 3/4 LN)

VariableEXT1/EXT2-Positive LMN, n=64/122 (52.5%)EXT1/EXT2-Negative LMN, n=96/252 (38.1%)P Valuea
Age at presentation, median (IQR), yr33 (25–42)38 (28–47)0.10
Female, n (%)57 (89.1)75 (78.1)0.07
SCr at presentation, median (IQR), mg/dl0.80 (0.60–1.00), n=610.90 (0.70–1.40), n=890.004
Proteinuria at presentation, median (IQR), g/24 h3.9 (1.6–6.7) n=533.0 (1.5–4.9), n=760.3
Proteinuria at presentation ≥3.5/d, n (%)32 (60.4), n=5333 (43.4), n=760.06
Hematuria, n (%)19 (29.7)35 (36.5)0.38
Proliferative features, n (%)16 (25.0)31 (32.3)0.32
Other autoimmune diseases, n (%)19 (29.7)22 (22.9)0.34
Sclerosed glomeruli, median (IQR), %0.0 (0.0–10.2)13.2 (1.82–25.0)<0.001
IFTA, median (IQR), %0.0 (0.0–0.0)10.0 (5.0–20.0)<0.001
SCr at end of follow-up, median (IQR), mg/dl0.90 (0.70–1.20), n=511.10 (0.70–1.60), n=710.05
Proteinuria at end of follow-up, median (IQR), g/24 h0.85 (0.20–2.00), n=360.90 (0.25–2.35), n=570.89
Proteinuria at end of follow-up ≥3.5/d, n (%)3 (8.3), n=369 (15.8), n=570.3
ESKD, n (%)2 (3.1)18 (18.8)0.003
Death, n (%)2 (3.1)8 (8.3)0.18
Time of follow-up, median (IQR), mo48.6 (33.1–76.5)50.6 (32.7–86.8)0.85
  • a P<0.05 is considered significant.